Quick Answer
Anebulo Pharmaceuticals, Inc. reported Total Assets of $12.15 million for the year ending 2025.
- Anebulo Pharmaceuticals, Inc. showed an increase of +198.2% in Total Assets from 2024 to 2025.
- This data is from Anebulo Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $4.29 million | Q3 2021: $20.50 million | Q4 2021: $18.96 million | Q1 2022: $17.25 million | Q3 2022: $19.82 million | Q4 2022: $16.89 million | Q1 2023: $14.43 million | Q3 2023: $9.05 million | Q4 2023: $7.50 million | Q1 2024: $6.00 million | Q3 2024: $2.47 million | Q4 2024: $15.84 million | Q1 2025: $14.01 million | Q2 2025: $12.15 million | Q3 2025: $10.70 million | Q4 2025: $9.42 million.
- Over the full 6 years of available data (2020 to 2025), Anebulo Pharmaceuticals, Inc.'s Total Assets has grown by 301.0%.
- Historical annual values: Fiscal year 2025: $12.15 million | Fiscal year 2024: $4.07 million | Fiscal year 2023: $11.67 million | Fiscal year 2022: $15.58 million | Fiscal year 2021: $21.65 million | Fiscal year 2020: $3.03 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: